参考文献/References:
[1] 付士辉,李玉龙,骆雷鸣,等. 高血压基础研究现状与进展[J]. 心血管病学进展,2019,40(9):1202-1205.
[2] de Miguel C,Pelegrín P,Baroja-Mazo A,et al. Emergingrole?of theinflammasome?andpyroptosis?inhypertension[J]. Int J Mol Sci,2021,22(3):1064.
[3] Valls RM,Pedret A,Calderón-Pérez L,et al. Effects?of?hesperidin?in?orange?juice?on?blood?and?pulse?pressures?in mildly hypertensive individuals:a randomized controlled trial(Citrus?study)[J]. Eur J Nutr,2021,60(3):1277-1288.
[4] Ulrich C,Wildgrube S,Fiedler R,et al. NLRP3 inflammasome activation in hemodialysis and hypertensive patients with intact kidney function[J]. Toxins(Basel),2020,12(11):675.
[5] Ferreira NS,Bruder-Nascimento T,Pereira CA,et al. NLRP3 inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus[J].?Cells,2019,8(12):1595.
[6] Li J,Teng X,Jin S,et al. Hydrogen sulfide improves endothelial dysfunction by inhibiting the vicious cycle of NLRP3 inflammasome and oxidative stress in spontaneously hypertensive rats[J].?J Hypertens,2019,37(8):1633-1643.
[7] Zhou W,Xi D,Shi Y,et al. MicroRNA19293p participates in murine cytomegalovirusinduced hypertensive vascular remodeling through Ednra/NLRP3 inflammasome activation[J]. Int J Mol Med,2021,47(2):719-731.
[8] Sun HJ,Ren XS,Xiong XQ,et al. NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension[J].?Cell Death Dis,2017,8(10):e3074.
[9] Ren XS,Tong Y,Ling L,et al. NLRP3 gene deletion attenuates angiotensin Ⅱ-induced phenotypic transformation of vascular smooth muscle cells and vascular remodeling[J].?Cell Physiol Biochem,2017,44(6):2269-2280.
[10] Zhang X,Hong S,Qi S,et al. NLRP3 inflammasome is involved in calcium-sensing receptor-induced aortic remodeling in SHRs[J].?Mediators Inflamm,2019,2019:6847087.
[11] Ling L,Chen D,Tong Y,et al. Fibronectin?type Ⅲ?domain?containing?5?attenuates?NLRP3 inflammasome activation and phenotypic transformation of adventitial fibroblasts in spontaneously hypertensive rats[J]. J Hypertens,2018,36(5):1104-1114.
[12] Han Y,Sun HJ,Tong Y,et al. Curcumin attenuates migration of vascular smooth muscle cells via inhibiting NFκB-mediated NLRP3 expression in spontaneously hypertensive rats[J]. J Nutr Biochem ,2019,72:108212.
[13] Qi HM,Cao Q,Liu Q. TLR4 regulates vascular smooth muscle cell proliferation in hypertension via modulation of the NLRP3 inflammasome[J]. Am J Transl Res,2021,13(1):314-325.
[14] Ren P,Wu D,Appel R,et al. Targeting the NLRP3 inflammasome with inhibitor MCC950 prevents aortic aneurysms and dissections in mice[J].?J Am Heart Assoc,2020,9(7):e014044.
[15] Gan W,Ren J,Li T,et al. The SGK1 inhibitor EMD638683,prevents angiotensinⅡ-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation[J].?Biochim Biophys Acta Mol Basis Dis,2018,1864(1):1-10.
[16] Pan XC,Liu Y,Cen YY,et al. Dual role of triptolide in interrupting the NLRP3 inflammasome pathway to attenuate cardiac fibrosis[J].?Int J Mol Sci,2019,20(2):360.
[17] Bautista-Pérez R,Pérez-Méndez O,Cano-Martínez A,et al. The role of P2X7 purinergic receptors in the renal inflammation associated with angiotensinⅡ-induced hypertension[J]. Int J Mol Sci,2020,21(11):4041.
[18] Doi T，Doi S，Nakashima A，et al. Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats[J].?PLoS One,2014,9(4):e93513.
[19] Sogawa Y,Nagasu H,Itano S,et al. The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice[J]. PLoS One,2018,13(10):e0203823.
[20] Zhang K,Fan C,Cai D,et al. Contribution of TGF-beta-mediated NLRP3-HMGB1 activation to tubulointerstitial fibrosis in rat with angiotensinⅡ-induced chronic kidney disease[J].?Front Cell Dev Biol,2020,8:1.
[21] Krishnan SM,Ling YH,Huuskes BM,et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure,renal damage,and dysfunction in salt-sensitive hypertension[J].?Cardiovasc Res,2019,115(4):776-787.
[22] Chen Z,Wu C,Liu Y,et al. ELABELA?attenuates?deoxycorticosterone?acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway[J]. Cell Death Dis ,2020,11(8):698.
[23] Chakraborty S,Galla S,Cheng X,et al. Salt-responsive metabolite,β-hydroxybutyrate,attenuates hypertension[J]. Cell Rep,2018,25(3):677-689.
[24] Chen YH,Chen HL,Fan HC,et al. Anti-inflammatory,antioxidant,and antifibrotic effects of kefir peptides on salt-induced renal vascular damage and dysfunction in aged stroke-prone spontaneously hypertensive rats[J]. Antioxidants(Basel),2020,9(9):790.
[25] Qi J,Yu XJ,Shi XL,et al. NF-κB blockade in hypothalamic paraventricular nucleus inhibits high-salt-induced hypertension through NLRP3 and caspase-1[J]. Cardiovasc Toxicol,2016,16(4):345-354.
[26] Wang ML,Kang YM,Li XG,et al. Central blockade of NLRP3 reduces blood pressure via regulating inflammation microenvironment and neurohormonal excitation in salt-induced prehypertensive rats[J]. J Neuroinflamm,2018,15(1):95.
[27] Hu L,Zhang S,Ooi K,et al. Microglia-derived NLRP3 activation mediates the pressor effect of prorenin in the rostral ventrolateral medulla of stress-induced hypertensive rats[J].?Neurosci Bull,2020,36(5):475-492.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(9):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(9):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(9):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(9):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(9):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(9):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]